deferiprone has been researched along with Diabetic Nephropathies in 4 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetic nephropathy was induced in rats by feeding on high-carbohydrate-fat food and injecting streptozotocin." | 1.39 | Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors. ( Bao, Y; Li, S; Liu, X; M, S; Sui, M; Xie, R; Yin, H; Zou, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhary, K | 1 |
| Chilakala, A | 1 |
| Ananth, S | 1 |
| Mandala, A | 1 |
| Veeranan-Karmegam, R | 1 |
| Powell, FL | 1 |
| Ganapathy, V | 1 |
| Gnana-Prakasam, JP | 1 |
| Zou, C | 2 |
| Xie, R | 2 |
| Bao, Y | 1 |
| Liu, X | 2 |
| Sui, M | 2 |
| M, S | 1 |
| Li, S | 1 |
| Yin, H | 1 |
| Liu, R | 1 |
| Wang, M | 1 |
| Mu, S | 1 |
| Li, L | 1 |
| Ji, L | 1 |
| Rajapurkar, MM | 1 |
| Hegde, U | 1 |
| Bhattacharya, A | 1 |
| Alam, MG | 1 |
| Shah, SV | 1 |
1 trial available for deferiprone and Diabetic Nephropathies
| Article | Year |
|---|---|
Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Diabetic Nephropathies; Drug Therapy, Combi | 2013 |
3 other studies available for deferiprone and Diabetic Nephropathies
| Article | Year |
|---|---|
Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload.
Topics: Animals; Deferiprone; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; | 2019 |
Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.
Topics: Animals; Deferiprone; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Iron Chelating Agents | 2013 |
Effect of the oral iron chelator deferiprone in diabetic nephropathy rats.
Topics: Administration, Oral; Animals; Blotting, Western; Chemokine CCL2; Cyclooxygenase 2; Deferiprone; Dia | 2017 |